Hims & Hers (NYSE: HIMS) has been on a wild journey over the past year as GLP-1s drive both big gains and big losses for the ...

Fintel reports that on January 10, 2025, Citigroup downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from Neutral ...

Shares in Hims Hers Health Inc (NYSE:HIMS) fell Friday after Citigroup (NYSE:C) analysts downgraded the stock to Sell/High Risk, citing overvaluation concerns tied to its GLP-1 revenue stream.

Hims & Hers Health (HIMS) stock gained after Citi upgraded the company, while agilon health (AGL) stock slipped after its downgrade. Read more here.

Citi downgraded Hims & Hers to Sell from Neutral with a $25 price target Stay Ahead of the Market:Discover outperforming stocks and invest ...

Citi downgraded Hims & Hers to Sell from Neutral with a price target of $25, up from $24. The firm thinks the market is overvaluing the ...

Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) have been given a consensus recommendation of “Hold” by the ...

Teladoc's growth and profitability challenges continue amid rising competition. Learn why TDOC stock remains under pressure with future uncertainties.

Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees ...

When it comes to the efficacy of a hair loss treatment, there’s nothing more telling than a before and after photo.

Forward, a tech-enabled, subscription-based primary care company, said it was shutting down 12 months after raising $100 million. Analysts predict it will be one of many companies to meet the same ...

Companies seeking to benefit from campaign promises to cut regulations and taxes are ditching diversity and climate ...